bcl-XS, a member of the bcl-2 family, has been shown to induce and/or sensitize some cells to undergo programmed cell death, and to negate the anti-apoptotic activity of bcl-XL and bcl-2 by mechanisms which are still uncertain. To help understand these mechanisms we have established stable derivatives of the K12 rat colon carcinoma cell line that express bcl-XS in a tetracyclineregulated manner, using an autoregulatory retroviral cassette. When bcl-XS expression is induced, we observe two phenotypic responses. A small fraction of cells appear to undergo spontaneous apoptosis while the majority of cells undergo a form of cytostasis. In the latter case, the cells stop dividing (or divide a limited number of times at a retarded rate) and swell to many times their original size. These cells can take on a ghostlike appearance and subsequently detach from the culture plates and die or they may remain intact in a hindered state of proliferation. Doubling times were calculated to be 31.4 h in the presence of tetracycline and 50.4 h without tetracycline, bcl-XS expression also causes dramatic alterations in the cell cycle distribution of K12 cells manifesting as a substantial decrease (&50%) in the fraction of S phase cells with a concomitant increase in the G1 population. Continuous expression of bcl-XS, at levels approximately equal to that of bcl-XL, decreased the viability of K12 cells as demonstrated by a log decline in clonogenic survival. This decrease occurred without considerable apoptosis or a compensatory increase in the level of bcl-XL. None of these phenotypes were present in control cells expressing b-galactosidase in a similar retroviral cassette. These observations demonstrate that bcl-XS can have substantial cytokinetic eects under circumstances that produce relatively little apoptosis.
Introduction
The bcl-2 family of proteins has been shown to alter the susceptibility of cells to undergo apoptosis (reviewed in Yang and Korsmeyer, 1996) . There are both pro-(bad, bax, bak, bik, hrk, bcl-XS) and antiapoptotic members (bcl-2, bcl-XL, Mcl-1) in this family although some genes may have contrasting eects in dierent cell lines, during various stages of dierentiation, or phases of the cell cycle (Ray et al., 1996; O'Reilly et al., 1996) . Alterations in expression of various bcl-2 family members can regulate tumorogenesis and response of cancer cells to cytotoxic therapies (Yang and Korsmeyer, 1996; Ealovega et al., 1996; Boise et al., 1993; Ray et al., 1996; Han et al., 1996) .
Dysregulation of apoptosis has been implicated in the pathogenesis of various diseases including colon cancer (Pritchard and Watson, 1996; Sinicrope et al., 1995) . There is substantial evidence that apoptosis decreases as colorectal cancer progresses. Bedi et al. (1995) have shown an incremental decrease of apoptosis in colorectal epithelial biopsies as tissue progresses from normal mucosa, to adenoma (both sporadic and familial adenomatous polyposis), to advanced carcinoma, and that this decrease may contribute to the progression of the disease. bcl-2, a key inhibitor of apoptosis, is expressed more often in adenomas than in carcinomas and it has thus been hypothesized that bcl-2 overexpression is an early event in colorectal carcinogenesis, preventing apoptosis of malignant seeds' (Pritchard and Watson, 1996; Bosari et al., 1995; Sinicrope et al., 1995) . Increased expression of bcl-XL and reduced bak expression have also been reported in some advanced colorectal cancers (Krajewska et al., 1996; Merchant et al., 1996) . This, coupled with the detection of varying levels of bcl-XS reported in normal colonic mucosa, adenomas and adenocarcinomas strengthen a possible role for this family of genes in the progression of neoplastic disease (Krajewska et al., 1996) . Dysregulation of bcl-2 family members has been implicated in chemoresistance of numerous cancers, including colorectal tumors, in which lack of the wild-type p53 transcriptional induction of bax and inhibition of bcl-2 may desensitize these cells to various insults (Miyashita et al., 1994; Zhan et al., 1994; Sinicrope et al., 1995; Ibrado et al., 1996; Han et al., 1996; Boise et al., 1993) .
Previously, the pro-apoptotic members of the bcl-2 family have been studied by transient assays, adenoviral infection, or derivation of stable cell lines. There are, however, inherent problems with each of these approaches such as a lack of quantitative reproducibility and heterogeneous expression among cells in transient transfections (Kitanaka et al., 1997) . Adenoviral infections often give highly ecient transduction but the infection process in itself can be quite toxic and it can prove to be dicult or impossible to distinguish a pro-apoptotic eect of a transgene from an additive or synergistic eect of transgene expression plus adenoviral infection . The selection of stable cell lines is limited by the level of expression that one may achieve without either co-transfecting an inhibitory, anti-apoptotic cDNA (Minn et al., 1996b) , or inadvertently selecting for mutations that may be directly or indirectly connected to the bcl-2 -apoptotic pathway(s). Recently, Wagener et al. (1996) used a tetracycline regulated expression system to study the eects of the bax-a gene. These regulated expression systems allow for the derivation of stable clones in which one may control the level of transgene expression (by altering the concentration of tetracycline in the media) as well as the timing of expression, including reversibility experiments. One also decreases the likelihood of selecting for mutations, as long as transgene expression is repressed during expansion. In the present study we have used a derivation of the original tetracycline regulated system (Gossen and Bujard, 1992) to produce stable derivatives of K12 rat colon carcinoma cells that express another proapoptotic member of the family, bcl-XS, using an autoregulatory retroviral cassette (Hofmann et al., 1996) . In these cells we have shown that bcl-XS has signi®cant cytokinetic eects as well as detrimental eects on clonogenic survival, without a dramatic increase in acute induction of apoptosis.
Results
Time course and tetracycline concentration-dependence of LacZ and bcl-XS-HA expression in stable derivatives of K12 cells After initial identi®cation of clones transduced with either the LacZ or bcl-XS-HA version of the TETregulated expression system shown in Figure 1 , one clone of each type was subcloned to ensure homogeneous transgene expression.
In the LacZ clone (K12Tet-LZ13.1), b-galactosidase activity was detectable after 2 days of withdrawal from tetracycline (TET) and peaked on day 5 with an approximate 500-fold induction in activity (Figure 2a) . Parental K12 cells were used as to obtain background luminescence levels which were subsequently subtracted from the sample values. Dependence of bgalactosidase activity on TET concentration was measured using day 4 as the endpoint of the experiment (Figure 2b ). An approximate IC 50 of 0.2 ng/ml was estimated for TET from this experiment; 0.7 ng/ml was the average IC 50 from three experiments (data not shown). Inhibition was detected with concentrations of TET as low as 0.1 ng/ml and expression was negligible with 3.0 ng/ml.
Analysis of transgene expression in the K12Tet-XS14.2 clone was performed using Western blotting. A time course showed the expression kinetics and TET dose response of bcl-XS-HA to be similar to the bgalactosidase results with bcl-XS detectable on day 2 and peaking on day 3 with an approximate induction of 150-fold and Figure  3b (anti-Bcl-X antibody)). The IC 50 for TET, determined using the anti-HA antibody, was found to lie between 1.0 and 3.0 ng/ml (Figure 3c and quantitative analysis using a Bio-Rad Molecular Imager, data not shown). Use of the anti-Bcl-X antibody ( Figure 3b ) allowed us to determine that during the induction of bcl-XS, there was no detectable compensatory increase in bcl-XL levels. Ratios of bcl-XS to bcl-XL obtained from a representative experiment showed that the highest ratio occurred on day 3 (0.76), then decreased slightly (0.51) and subsequently remained constant through the rest of the time course.
Morphological changes resulting from bcl-XS expression in K12 cells
During preliminary experiments, two aberrant morphologies were observed in the K12Tet-XS14.2 cells as a result of induction of bcl-XS expression. The predominant phenotype was characterized by a decreased rate of proliferation and gross cellular swelling with apparent sporadic multinucleation ( Figure 4B ). These cells took on a ghost-like appearance and could subsequently detach from the culture plates and die or they may remain intact in a reduced proliferative state. A smaller fraction of bcl-XS expressing cells showed a decrease in cytoplasmic volume and detached from the dish shortly after transgene expression reached maximum levels (day 3), with the gross appearance of apoptotic cells ( Figure  4C ). Neither of these phenotypes was observed to a signi®cant degree in K12Tet-XS14.2 cells maintained in TET ( Figure 4A ) or in K12Tet-LZ13.1 cells grown with or without TET (not shown). Figure 1 Schematic representation of the pTetRet (pBABE SINRetroTet 15-1) vector. Upon transfection of the retroviral construct (a) into producer cells, the major transcript is made utilizing the 5' LTR as a strong promoter/enhancer. This transcript is packaged to produce retrovirus which is then used to infect target cells. After integration into the target cell genome (b), the functional 5' LTR has been replaced with the 3' LTRD which has been mutated to inactivate its promoter/enhancer activity. Therefore, in the target cell only the CMV minimal promoter is able to drive transcription of the bicistronic mRNA. These transcripts code for both the desired transgene and, by means of an internal ribosome entry site (IRES), for the tetracycline transactivator (tTA), which is a fusion of a tetrepressor domain and a transcriptional enhancer domain (VP16). In the presence of tetracycline, the tTA becomes allosterically altered and cannot bind to the tetracycline operator (tetO) sequences and expression is minimal. However, when tetracycline is withdrawn the tTA binds to the heptamerized tetO sequence bringing its enhancer domain close enough to the minimal CMV promoter to activate it. As a result, a feed-forward loop is initiated in which the simultaneous production of transgene and tTA accelerates as more tTA accumulates bcl-XS expression alters proliferation rate and cell cycle distribution of K12 cells
The apparent decrease in growth rate of cells expressing bcl-XS was con®rmed by quantitative analysis ( Figure 5 ). K12 cells expressing bcl-XS had a doubling time of 50.4+6.0 h (n=4) while nonexpressers (+ TET) doubled every 31.4+2.4 h (n=3). K12Tet-LZ13.1 cells, grown with or without TET, had doubling times of 31.7 and 35.5 h respectively (average of two experiments). The eect of bcl-XS on the growth rate may be underestimated due to the lag time of the expression system as growth curves were followed for seven days and, as was shown previously, it was not until the third day that bcl-XS expression was induced fully.
To determine if the decrease in growth rates in bcl-XS expressing cells is re¯ected by changes in the cell cycle distribution we performed 2-parameter¯ow cytometric analysis of K12Tet-XS14.2 cells at various times after TET withdrawal. Results from four experiments showed a reproducible decrease in S phase cells as TET was withdrawn from the K12Tet-XS14.2 cells (Figure 6 ). Almost one half of the S phase population was redistributed in the cell cycle with most of the cells accumulating in G1. There also appears to be a slight increase in the tetraploid population; however, due to the aneuploid nature of K12 cells, we have not been able to distinguish a rise in premitotic diploid cells from an increase in tetraploid G1 cells. It should be noted that this partial (&50%) loss of S phase cells may be incomplete because of the heterogeneous expression of bcl-XS apparent in Figure  9a . The pattern of higher transgene expression in the peripheral cells is not unique to bcl-XS and was also seen in the K12Tet-LZ13.1 cells expressing b-galactosidase (data not shown). This expression appears to be an artifact of the expression system as HT29 cells displayed a similar pattern; however 3T3 clones were much more homogenous in their expression (data not shown). K12Tet-LZ13.1 cells did not show a decrease Figure 2 Time course (a) and concentration-dependence (b) of tetracycline-regulated LacZ expression in K12Tet-LZ13.1 rat colon carcinoma cells. Cells were plated and grown for 2 days in the presence of 1 mg/ml tetracycline at which point the culture media was changed either to no tetracycline (a) or to the indicated concentrations (b) (t=0). Cells were harvested either daily (a) or on day 4 (b). Tissue culture media was changed daily. Activity was detectable after 2 days and peaked on day 4 or 5 with an approximate induction of 500-fold. Each value represents the mean of duplicate samples from one experiment. Similar results were obtained in another experiment Figure 3 Time course (a and b) and concentration-dependence (c) of tetracycline-regulated Bcl-XS expression in K12Tet-XS14.2 rat colon carcinoma cells. In time course (a and b) and concentration-dependence (c) experiments, cells were plated and grown for 2 days in the presence of 1 mg/ml tetracycline at which point the culture media was changed either to no tetracycline (a and b) or to the indicated concentrations (for 4 days) (c) (t=0). An anti-HA (a and c) or an anti-Bcl-X (b) antibody was used to detect the proteins of interest. Bcl-XS expression was detectable on day 2 and peaked on day 3 or 4 with an induction of at least 150-fold over basal levels in the S phase population as TET was withdrawn (data not shown). In addition, the broad spectrum caspase inhibitor zVAD-fmk (50 mM) was unable to revert the cytokinetic changes seen in the bcl-XS cells and they are therefore unlikely to be mediated by these proteases (data not shown).
We next examined the eect of bcl-XS expression in 3T3 cells using the same tetracycline regulated expression system to determine if the cytokinetic was unique to the K12 cells. Three clones were assayed for cytokinetic changes; however, we were unable to perform 2-parameter¯ow cytometry on two of the clones as they underwent extensive apoptosis. The third clone was viable and its cell cycle was undisturbed by the expression of bcl-XS (data not shown). This illustrates that the eects of bcl-XS can be dierent even in similarly derived clones and it would therefore be necessary to examine a large number of clones (derived from K12 and other cell lines) using the same expression system to see if this cytokinetic eect is Figure 4 Phenotypic eects of Bcl-XS expression in K12 cells. Cells were plated and grown overnight in the presence of 1 mg/ml tetracycline at which point the culture media was changed to either no tetracycline (B and C) or maintained in media containing 1 mg/ml tetracycline (A) (t=0). A represents a typical`expression o' phenotype while B and C represent the predominant and less common`expression on' phenotypes, respectively unique to colon carcinoma cells or is one of several possible phenotypes induced by bcl-XS expression.
Eects of bcl-XS expression on long-term and acute endpoints for toxicity
Conditional expression of bcl-XS decreased the shortterm (11 day) clonogenicity of K12 cells in a dose dependent manner with 14.4% survival at maximal bcl-XS expression (Figure 7 ). Long-term clonogenic survival (21 days) under the same experimental conditions was 37% (Table 1) . It should also be noted that roughly 75% of the surviving colonies grown without TET had an abnormal morphology consisting of enlarged and vacuolized cells that were not immediately adjacent to each other, as was the case when grown in the absence of bcl-XS expression. Addition of zVAD-fmk (50 mM) during the duration of the experiment was unable to increase clonogenic survival or revert the abnormal morphology of the surviving colonies (data not shown).
Having previously determined that bcl-XS expression decreases the growth rate and long-term survival of K12 cells we assessed if one of the contributing factors to both of these phenotypes was an increased level of apoptosis. Three methods for detecting apoptosis were employed: sub-2N levels of DNA content (determined by propidium iodide staining and ow cytometry), nuclear morphology (viewed bȳ uorescent microscopy of DAPI stained cells), and externalization of phosphatidylserine on the plasma membrane as detected by annexin V binding and uorescent microscopy (van Engeland et al., 1998) . Flow cytometry of propidium iodide stained K12Tet-XS14.2 cells as they are withdrawn from TET showed no signi®cant increase in the fraction of cells possessing less than their 2N complement of DNA Figure 5 Growth rate eects of Bcl-XS expression in K12 rat colon carcinoma cells. Cells were plated and allowed to grow for 2 days in the presence of 1 mg/ml tetracycline at which point the culture media was changed to either no tetracycline (7TET) or maintained in 1 mg/ml tetracycline (+TET) (t=0). Media was thereafter replaced once a day. Triplicate samples were counted daily and doubling times of 1.31 (+ TET) and 2.1 (7TET) days were calculated from linear regressions of log transformed normalized growth curves. K12pTetRetLZ 13.1 cells did not show a signi®cant dierence in log phase growth rate+TET. Data represents the mean of four experiments+s.e.m. Figure 6 Cytokinetic eects of Bcl-XS expression in K12 cells. Cells were plated and grown for two days in the presence of 1 mg/ ml tetracycline at which point the culture media was changed to no tetracycline (t=0). Media was thereafter changed once a day. Samples were collected at daily intervals following a 15 min BrdU pulse (30 mM ®nal concentration). Cells were then ®xed and analysed by two parameter¯ow cytometry for BrdU and DNA content. Results show a loss of approximately one half of the S phase population. Data represents the average of either three or four experiments+s.e.m.
Figure 7
Tetracycline dependent clonogenic survival of K12Tet-XS14.2 and K12Tet-LZ13.1 cells. Five hundred cells were plated in tissue culture¯asks and grown for 2 days in the presence of 1 mg/ml tetracycline. Culture media was then changed to the indicated tetracycline concentrations and replaced once a day (t=0). After 11 days, cells were ®xed and stained for counting. Percent survival was calculated as the number of colonies (5256 cells) present at each concentration of tetracycline, divided by the number of colonies at 1000 ng/ml, multiplied by 100. K12Tet-XS14.2 data represents three experiments+s.e.m. except for 1 mg/ ml, which represents the mean of two experiments as does the K12Tet-LZ13.1 data when compared to K12Tet-LZ13.1 cells until day 3 (Figure 8a ). Treatment of parental K12 cells with 100nM¯uorodeoxyuridine (FdUrd) for 48 h served as the positive control for this assay as this population showed a signi®cant fraction (&24%) of cells containing sub-2N DNA. We also examined the nuclear morphology of DAPI stained K12Tet-XS14.2 and the K12Tet-LZ13.1 cells as they were withdrawn from TET ( Figure 8b) . A similar level of apoptosis was seen using this assay. It is apparent from these experiments that expression of bcl-XS in K12 cells causes a small but statistically signi®cant increase in acute apoptosis. The ability of bcl-XS to sensitize K12 cells to undergo apoptosis induced by either UV light (&8 J/cm 2 ) or FdUrd was examined by¯ow cytometry of propidium iodide stained cells. K12Tet-XS14.2 cells were withdrawn from TET for 3 days at which time they were treated with FdUrd or UV light. Levels of apoptosis were obtained 48 h after treatment and no sensitization was seen from bcl-XS expression (data not shown).
Dual color¯uorescence microscopy was performed using annexin V-biotin and an anti-HA anitbody to ascertain if the cells that were apoptotic also expressed more bcl-XS than their non-apoptotic counterparts. Annexin V externalization was chosen as the marker of apoptosis as this has been shown to be an early event in apoptosis and would allow detection of both bcl-XS and apoptosis before possible proteolysis. There was not a qualitative correlation between annexin positive cells and high levels of anti-HA staining as all permutations were readily detected (Figure 9b and data not shown).
Discussion
In the present study, we sought to characterize the eects of bcl-XS expression in K12 rat colon carcinoma cells utilizing a tetracycline regulated retroviral expression system. We con®rmed that bcl-XS expression was highly regulated in these cells in a tetracycline (TET) dependent manner. The time course and TET dose-dependent expression of bcl-XS was similar to that of b-galactosidase expressing cells. Expression of bcl-XS caused two phenotypes not present in cells expressing b-galactosidase. The predominant phenotype is characterized by a decreased growth rate accompanied by gross cellular swelling and sporadic multinucleation. The less common phenotype was classi®ed as apoptotic by virtue of morphological changes seen by phase contrast microscopy: cytoplasmic shrinkage, loss of cell contact, and rounding and eventual detachment from the culture dish. Because of the slowed proliferation of K12Tet-XS14.2 cells, we examined their cell cycle distribution and found that the proportion of S phase cells dropped nearly in half with a concomitant increase mainly in the G1 population. Lastly, we examined the eects of bcl-XS expression on viability and found a bcl-XS-dose dependent reduction of survival with a conservative estimate of a 60% loss of clonogenic cells at maximal expression of bcl-XS. Data was collected for clonogenic survival at both 11 and 21 days after TET withdrawal and two thresholds were subsequently used to de®ne a colony (Table 1) . We began with the prototypical guidelines of approximately 10 days of growth and de®ned a colony as having at least 50 cells; however, we were concerned that the loss of clonogenic survival we observed was due in part to the observed retarded growth rate caused by expression of bcl-XS and not to a true loss of clonogenicity. To address this question we looked at the longer (21 day) time point as well as using a more stringent de®nition of a colony (256 cells). This de®nition was chosen from the observation that the b-galactosidase expressing cells had a doubling time of 33.6 h and therefore would have doubled eight times in 11 days forming a colony of 256 cells. We concluded from the data in Table 1 that the decreased growth rate from expression of bcl-XS did cause an apparent decrease in clonogenic survival but that this eect was insucient to account for the approximate one log loss of clonogenicity.
Studying genes that encode for toxic products, such as bcl-XS, presents some unique problems. Transient Figure 8 Bcl-XS induced apoptosis in K12 rat colon carcinoma cells. Cells were plated and grown for 2 days in the presence of 1 mg/ml TET at which point the culture media was changed to no TET (t=0). Media was thereafter changed once a day. Samples were ®xed and analysed for DNA content (a) or nuclear morphology (b). In a and b, the white bars represent K12Tet-XS14. transfection systems are often used but artifacts and problems with reproducibility limit their usefulness (Kitanaka et al., 1997) . Generating stable clones is often impossible and any resulting clones may have been selected on the basis of altered expression of secondary genes that enhance survival; in addition, these clones generally express minimal levels of transgene (Nunez, personal communication). We have circumvented these problems utilizing a tetracyclinerepressible expression system (Figure 1) (Hofmann et al., 1996) . This system is a modi®cation of the original TET system of Gossen and Bujard (1992) Bcl-XS expression and annexin V staining as detected by¯uorescence microscopy. Cells were plated and grown in the presence or absence of TET (1 mg/ml) for 4 days at which time they were incubated with annexin V-biotin (b) and subsequently ®xed and incubated with an anti-HA antibody followed by an anti-mouse-Texas Red (a and b) and NeutrAvidin-Alexa 488 (b). a shows the expression pattern of bcl-XS-HA in the presence or absence (4 days) of TET (1 mg/ml). Note that the highest level of expression is detected at or near the periphery of the colony. b shows a ®eld of cells grown in the absence of TET for 4 days photographed by phase contrast (upper left), anti-HA-Texas Red¯uorescence (upper right), annexin V-Alexa-488¯uorescence (lower left) and dual uorescence microscopy (lower right). Apoptotic cells are indicated by arrows in b. This ®eld does contain more than a representative number of apoptotic cells and was chosen only to illustrate the lack of a qualitative correlation between high levels of bcl-XS expression and apoptosis possesses a number of advantages for our purposes. Expression of the tetracycline trans-activator (tTA) and transgene are driven from a single transcript utilizing a viral internal ribosome entry site (IRES), limiting the number of independent genetic elements required. This system also possesses an auto-regulatory feedback loop (neither the tTA nor the transgene is produced at signi®cant levels unless tetracycline is absent), eliminating possible artifacts (such as transcriptional squelching) from constitutive tTA expression (Iida et al., 1996) . Lastly, the system is introduced into target cells via a retrovirus allowing transduction of cells that are inherently dicult to transfect or for use in vivo to assess novel gene therapy protocols in a regulated fashion (Dhawan et al., 1995; Iida et al., 1996; Furth et al., 1994; Shockett et al., 1995) . Drawbacks of this system include the heterogeneous expression seen in Figure 9 . This expression pattern is not unique to K12 cells as it was seen another carcinoma cells line (HT29s) but it is also not universal as it was not apparent in 3T3 clones (data not shown). Also, there is the lack of a selectable marker in this expression cassette, so having a reasonably high infection eciency is important to limit the number of clones screened. To maximize the transduction eciency of K12 cells, we opted for a course of multiple infections (Noel et al., 1994) .
Recently several investigators have attempted to study a possible role for bcl-XS in gene therapy, in vitro and in vivo. These investigators observed cell death (characterized as apoptosis) from adenoviral infection of bcl-XS in human breast cancer, neuroblastoma, and colon cancer cells Dole et al., 1996; Ealovega et al., 1996) . However, in some cases there was also signi®cant death caused by infection with control (b-galactosidase) adenovirus and the use of such a system make it impossible to distinguish whether bcl-XS expression is lethal by itself or merely if it is sensitizing cells to the toxic insult of adenoviral infection. Others have shown only a sensitizing eect of bcl-XS, causing increased death under sub-optimal growth conditions, treatment with chemotherapeutics or radiation (Boise et al., 1993; Ray et al., 1996; Minn et al., 1996b) . In our system expression of bcl-XS by itself is insucient to induce apoptosis to a large extent (i.e. 410%). The low level of apoptosis observed upon expression of bcl-XS does not appear to be caused by an intrinsic inability of K12 cells to undergo a programmed cell death response, as K12 cells do undergo apoptosis upon treatment with uorodeoxyuridine ( Figure 8 ) or cycloheximide (data not shown) for 48 h, as determined by nuclear morphology and¯ow cytometric analysis of DNA content. We considered that the failure of bcl-XS to cause a large acute apoptotic response might be due to endogenous levels of the antagonistic protein bcl-XL. However, Figure 3b shows that the ratio of bcl-XS to bcl-XL obtained in our system are comparable to, if not higher than, those seen in the adenoviral experiments cited previously. Therefore, this ratio is clearly not, by itself, a good prognostic factor for bcl-XS induced death.
Although bcl-XS expression did not cause extensive acute death in K12 cells, it did cause signi®cant retardation of growth, cell cycle redistribution, and decreased clonogenic survival in this cell line. Neither the cell cycle redistribution or loss of clonogenicity were inhibitable by the broad spectrum caspase inhibitor zVAD-fmk (50 mM) and are therefore not likely to have been the result of caspase activation. We do however recognize the fact that the inhibitor may not be broad enough in its activity or ecacious enough at the concentration used to rule out the possibility of caspase involvement.
Since there have been relatively few studies published concerning the eects of expression of bcl-2 family members on cell cycle regulation, it is too early to draw conclusions about whether or not such regulation is a general property of these proteins, or to predict the changes in cell cycle distribution that they might cause. In T cell populations from baxaexpressing transgenic mice, it was found that entry into S phase (from quiescence) was accelerated, in comparison to controls (Brady et al., 1996) , whereas the opposite eect (i.e., delayed S phase entry) was observed in bcl-2-expressing transgenic mice (also from a quiescent state) (O'Reilly et al., 1996) . From these observations one might begin to form a model in which enhancement or attenuation of cell cycle progression is associated with pro-or anti-apoptotic members of the family, respectively. However, such a model would be inconsistent with our ®nding that a pro-death protein (bcl-XS) caused redistribution of cells from S to G1 phase of the cell cycle unless one considers the fact that bcl-XS is a rather unique pro-death protein. Bcl-XS shares properties of both the pro-and anti-death members of the bcl-2 family: it has a BH4 domain (indicative of anti-apoptotic members), yet it has been shown (when expressed at supraphyisological levels) to induce or sensitize cells to die (Minn et al., 1996b; Sumantran et al., 1995; Clarke et al., 1995; Dole et al., 1996; Ealovega et al., 1996; Boise et al., 1993; Ray et al., 1996) .
It is also possible that the cell cycle regulatory properties of these proteins might be completely unrelated to their eect on apoptosis, and that each member of the family might have its own characteristic eect on the cell cycle. We note, for example, that ectopic expression of bcl-XL in FL5.12 cells induced spontaneous accumulation of tetraploid cells and perturbation of expression of some cyclins (Minn et al., 1996a) . Although we have not yet examined the eect of bcl-XS expression on cyclins or on CDK (cyclin-dependent kinase) activity, we did observe extensive multinucleation during bcl-XS-expression.
More work needs to be done to determine if the cell cycle eects of bcl-XS are independent from its apoptotic eects, as was shown to be case for bcl-2 (Huang et al., 1997) , and to de®ne a pathway linking bcl-XS to the cell cycle. Dierentiating a cell cycle role for bcl-XS from an apoptotic role is a more challenging problem and is the subject of continuing investigation.
Materials and methods

Reagents
Tetracycline-hydrochloride, ammonium persulfate, ethidium bromide, anti-HA antibody, and a protease inhibitor cocktail (Complete) were supplied by Boehringer Mann-heim (Indianapolis, IN) . Protein assay kits were obtained from Bio-Rad (Hercules, CA). Molecular-grade agarose, DMEM, fetal bovine serum, calf serum, antibiotic solutions, and DH5a competent cells were purchased from 
Plasmid construction
The bcl-XS-HA cDNA was cut out of the pSFFV-neo vector using¯anking EcoRI sites (a gift from Dr Gabriel Nunez). pBABE SIN-RetroTet 15-1 (pTetRetLacZ) was also cut with EcoRI which dropped out a 3.4 kbp LacZ fragment and the bcl-XS-HA cDNA was subsequently ligated in. Directional cloning was con®rmed by diagnostic enzyme digestions.
Cell culture K12 cells were obtained from Francois Martin and maintained in DMEM medium (Gibco/BRL) supplemented with calf serum to 10% (v/v) and L-glutamine to 2 mM (Caignard et al., 1985) . FNX-ampho cells (a derivative of 293T cells) were obtained from Dr Gary P Nolan and were grown in DMEM medium (Gibco/BRL) supplemented with fetal bovine serum to 10% (v/v) and L-glutamine to 2 mM. HT29 LacZ cells were grown in McCoy's 5A medium supplemented with fetal bovine serum to 10% (v/v) and L-glutamine to 2 mM. All cells and were grown as monolayers at 378C humidi®ed at 5% CO 2 , except the retroviral producer cells during retrovirus production (328C).
Retrovirus production and infection
FNX-ampho retroviral producer cells were transiently transfected with one of the retroviral constructs using a CaPO 4 and chloroquine protocol (Nolan, personal communication). After 10 h, the transfection mix was aspirated and the media was changed to normal growth media (DMEM with 10% calf serum and antibiotics). The following day the media was changed again and the cells were moved to a 328C incubator for viral production. After 12 h the media was aspirated, placed on ice, and replaced with fresh media. The aspirated media was ®ltered through a 0.2 mm syringe ®lter and the ®ltrate was frozen immediately at 7708C. Every 3 h (for 12 h) the media was harvested and treated as before. The producer cells were then stained with X-gal or analysed by¯ow cytometry (using an anti-HA antibody) to con®rm transfection eciency.
K12 cells were plated in 60 mm culture dishes at a density of 1610 5 cells/dish and left to grow overnight. The following morning the media was replaced with a freshly thawed aliquot of the retroviral supernatant. Polybrene was added to a ®nal concentration of 8 mg/ml. The cells were left at 378 for 3 h at which time the media was aspirated and the cells were washed with 5 ml of normal growth media. A fresh aliquot of retroviral supernatant and polybrene was added to the cells for another 3 h. This was repeated for a total of ®ve infections with the last infection proceeding overnight. The following morning the media was again aspirated and replaced with normal growth media containing 1.5 mg/ml doxycycline. Twenty-four hours later, the cells were trypsinized, counted and plated in 96-well culture plates at densities of 0.5, 1.0, 2.5, or 5.0 cells/well in normal growth media containing 1.5 mg/ml doxycycline. Media was changed every 2 days to ensure repression of transcription by doxycycline. Cells were cloned in 96-well plates to prevent the possibility of overlooking growth inhibited colonies that may be missed on a larger culture dish. After approximately 1 week, each well in the 96-well plates was examined to determine the number of colonies present. Only wells containing single colonies were assessed for regulated gene expression. Colonies were later subcloned to ensure a monoclonal population.
Assaying regulated lacZ expression
Initial determination of regulated lacZ expression was assessed by dierential X-Gal (5-bromo-4-chloro-3-indolylb-D-galactoside) staining of clones grown + doxycycline (with daily media changes). Brie¯y, the cells were grown with or without doxycycline until approximately 80% con¯uent (at least 4 days) at which time the media was aspirated, the cells were rinsed with PBS and then ®xed for 10 min in 0.5% gluteraldehyde. Cells were then incubated twice for 10 min in PBS containing 1 mM MgCl 2 . A staining solution containing 1 mg/ml X-Gal was added to the cells and they were left overnight at 378C. The following morning, the cells were examined for differential blue staining (+ doxycycline). Quantitative dierences of lacZ expression were assessed using the Galacto-Light Plus Assay Kit (Tropix, Inc., Bedford, MA). Brie¯y, 1610 5 cells were plated in two wells of a 6-well culture dish and grown + doxycycline for 4 days. The media was then aspirated and the cells rinsed twice with PBS. Lysis buer was added to the cells and the lysate was subsequently spun at full speed for 2 min in a microcentrifuge. The supernatant was placed into a fresh microfuge tube and frozen at 7708C. Equivalent amounts of protein from each sample were used in the assay following the manufacturer's protocol and samples were examined in a Berthold LB95291 luminometer.
Quantifying bcl-XS-HA expression bcl-XS-HA infected clones were initially examined by¯ow cytometry using an anti-HA primary antibody (Boehringer Mannheim) and a phycoerythrin-conjugated secondary antibody (Sigma #P-0313) to circumvent the problem of an arti®cial rightward shift from the doxycycline when using the FL1 channel and a FITC-conjugated antibody. Colonies were grown + doxycycline (with daily media changes) in 6-well culture dishes for at least 4 days (until they were 80% con¯uent). The cells were then ®xed in paraformaldehyde and incubated with primary and secondary antibodies in the presence of saponin (0.3%) and normal goat serum (33%). Cells were analysed in a FACScan¯ow cytometer using the Lysis II software (Becton Dickinson).
Western blots were used to reassess regulated clones identi®ed by¯ow cytometry. Cells were grown + doxycycline (with daily media replacement) for 4 days. The cells were then trypsinized, counted, and lysed in Lamelli's sample buer with 5% b-mercaptoethanol (Lamelli, 1971) . Equal numbers of cells were loaded in each lane of SDSpolyacrylamide gels and the resolved proteins were subsequently transferred onto a nitrocelluose membrane (Immobilon-P). Membranes were then blocked with a 5% milk solution and then incubated with primary anti-HA antibody (1 mg/ml), and subsequently a 1 : 100 000 dilution of a horseradish peroxidase-conjugated secondary antibody (Sigma #A-0168). The SuperSignal ULTRA chemiluminescent detection substrate (Pierce) was used to visualize the secondary antibody bound to the speci®c protein (following manufacturers protocols).
Time course and tetracycline concentration dependent Bcl-XS expression experiments was also analysed by Western blot with minor changes to the protocol. A NP-40 lysis buer (per 100 ml: 2 ml NP-40, 1.75 g NaCl, 10 ml 1 M Tris (pH 8), 1 ml 10% SDS) containing the complete protease inhibitor cocktail (Boehringer Mannheim) was used to lyse the cells and protein concentrations were determined using the Bio-Rad D c Detection Kit. Equal amounts of protein (approximately 15 mg) were loaded in each lane, except for the FL5.12 positive control cells which were loaded identically from experiment to experiment to serve as an internal standard for signal strength. Western blots were transferred and probed as previously described. Quantitative data was obtained by exposing the chemiluminescent membranes on a Bio-Rad imaging screen and analysis with a Bio-Rad Molecular Imager and accompanying analysis software.
Photomicroscopy K12Tet-XS14.2 cells were plated onto T-75 tissue culturē asks or 100 mm dishes in the presence of 1.0 mg/ml TET. Cells were allowed to grow overnight at which time the dishes/¯asks were observed, under phase contrast microscopy, for suitable areas to photograph (t=0). The exact position on the plate was marked so that superimposable pictures could be taken for daily monitoring. Growth media was changed daily, after photomicrography, to eliminate TET regulated inhibition of expression.
Growth rate determination
1610
4 cells were plated into each well of 6-well tissue culture dishes in the presence of 1 mg/ml TET and allowed to grow for 2 days (t=0). Daily cell counts were taken by aspirating the growth media from triplicate wells, trypsinzing the cells, and counting them using a Z1 Coulter Counter. Growth media (without TET) was replaced daily for all remaining time points.
Cell cycle analysis
Cells were plated at a range of densities so they were approximately 50 ± 70% con¯uent at the time of harvest. After trypsinization, cells were washed twice with PBS, ®xed in ice-cold ethanol (70%), and stored at 48C. Samples were analysed by two-parameter¯ow cytometry measuring BrdU incorporation and DNA content in at least 25,000 cells as described by Hoy et al. (1989) on a FACScan¯ow cytometer using FCAP-list software (Soft Flow, Inc., Burnsville, MN) to quantify the data.
Clonogenic survival
Five hundred cells were plated in T-75 tissue culture¯asks and grown for 2 days in the presence of 1 mg/ml TET (t=0). Growth media was then changed to contain a range of concentrations of TET and thereafter replaced daily. After 11 days one of a duplicate set of plates for each concentration of TET was ®xed with methanol and acetic acid and stained with trypan blue dye. Clusters of cells were counted and classi®ed as colonies using either 50 or 256 cells as a threshold.
Quantifying apoptosis
Apoptosis was quanti®ed by examining both the nuclear morphology of the cells and the per cent of the cell population that possessed less than their normal diploid DNA content. DNA content was measured by¯ow cytometry of ®xed cell stained with propidium iodide. Brie¯y, cells were plated in the presence of TET (1 mg/ml) and allowed to grow for 2 days at which time media was changed to contain no TET and the ®rst of daily samples was trypsinized and ®xed in ice-cold 70% ethanol (t=0). Growth media was replaced and samples were taken daily. Samples were stained at the same time by washing the cells twice with PBS and resuspended in a 1 : 10 dilution of a 106staining solution (0.18 mg/ml propidium iodide and 0.4 mg/ml RNaseA) and PBS at a concentration of 16106 cells/ml. Cells were stained overnight in the dark at 48C and analysed the following day in a FACScan¯ow cytometer (using the FL2 channel) with the LYSIS II software (Becton Dickinson).
Nuclear morphology was assessed by staining cells with DAPI (4',6-diamidino-2-phenylindole), a DNA speci®c dye and¯uorescent microscopy. A range of numbers of cells, 2.5610 4 to 5610 3 , were plated on Lab-Tek Chamber Slides (Nunc, Inc.) in the presence of 1 mg/ml TET and allowed to grow for 2 days (t=0). Growth media was hereafter replaced and collected daily by rinsing the slide twice with PBS and ®xing in 4% paraformaldehyde for 30 min. Samples were then rinsed twice and stored with PBS at 48C. All samples were stained at the same time by adding 100 mL of a 0.5 mg/ ml DAPI stock solution to 2 ml of PBS and incubating for 30 min at room temperature in the dark. The slides were then removed from the culture chambers, washed three times with PBS, allowed to air dry in the dark, then mounted with glass cover slips. Cells were then visualized using a LaborLux D uorescent microscope (Leitz) and a 515 ± 560 nm excitation ®lter. Three hundred cells were counted from random ®elds and apoptotic events were identi®ed by a characteristic staining pattern of condensed chromatin (usually at the nuclear periphery) often accompanied by shrunken cytoplasm.
Fluorescence microscopy
Phosphatidylserine externalization and bcl-XS-HA expression levels were determined either exclusively or simultaneously by growing cells (1.0610 4 to 2610 3 ) on Lab-Tek 2-well Chamber Slides in the presence or absence of TET (1 mg/ml) for 4 days at which time they were prepared for analysis. Slides in which apoptosis was to be detected were incubated with annexin V-biotin in the supplied binding buer for 15 min at room temperature and then ®xed in 2% paraformaldehyde (with 2.0 mM CaCl 2 ) for 10 min. Cells were then washed twice with PBS. All samples were then permeabilized and blocked in PBS with 0.05% NP-40 and 5% calf serum (BP buer) for 15 min. A mouse monoclonal anti-HA antibody (or isotype control) was then added at a ®nal concentration of 10 mg/ml (in BP) and incubated for 30 min. The slides were washed three times with PBS and a 1 : 200 dilution of a Texas Red conjugated secondary antibody was added in BP. Slides which were previously incubated with annexin V-biotin also had NeutrAvidin Alexa 488 (Molecular Probes, Inc.) added at 5 mg/ml (control samples were also examined in the presence of annexin V without addition of NeutrAvidin) and incubated for 30 min at room temperature in the dark. Cells were washed three times and slides were mounted using Vectashield (Vector Laboratories) and glass cover-slips. Photomicroscopy was performed on an Olympus inverted¯uorescence microscope with the appropriate single or dual channel wavelength ®lters.
